Diamond Biotechnology Co., Ltd (6815.TWO) Stock

6815.TWO logo

Diamond Biotechnology Co., Ltd

6815.TWOTaiwan
Healthcare

Company profile

Diamond Biotechnology reported revenue of 501.49 million TWD for fiscal year 2025. Our analysis of its filings shows revenue shrinking from 616.10 million TWD in fiscal year 2023 to 501.49 million TWD in fiscal year 2025, 9.8% a year on average.

What stands out

  • Revenue fell 34.7% in fiscal year 2025, from 768.25 million TWD in fiscal year 2024, after a rise of 24.7% the year before.
  • It reported a net loss of 70.31 million TWD in fiscal year 2025, after a profit of 73.20 million TWD in fiscal year 2024.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Diamond Biotechnology Co., Ltd

Diamond Biotechnology Co., Ltd engages in the research, development, manufacture, and sale of health care products and medical consumables in Taiwan and internationally. The company offers Miracle Thread, an absorbable synthetic surgical suture device made of polydioxanone; UTIMS, a high-intensity focused ultrasound; Letybo, a frozen crystal injection; TEOSYAL RHA invisible resilient hyaluronic acid; Ronkyla, a sodium deoxycholate injection; S+DIAMOND skincare products. It also sells and leases medical equipment. The company was founded in 2014 and is based in Taipei, Taiwan.

Leadership

  • Ting Yu Zhang — Accounting Supervisor

How much revenue does Diamond Biotechnology make?

Diamond Biotechnology reported 501.49 million TWD in revenue for fiscal year 2025, down 34.7% from 768.25 million TWD in fiscal year 2024.

What companies are similar to Diamond Biotechnology?

Listed companies of a similar size in the same industry (targeted healthcare equipment) include Medimaging Integrated Solution Inc. (6796.TW), Taiwan Biomaterial Co., Ltd. (6649.TWO), NaviFUS Corp. (6872.TWO), Polylite Taiwan Co., Ltd. (1813.TWO).

How has Diamond Biotechnology's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 395.20 million TWD; FY2022, 434.84 million TWD; FY2023, 616.10 million TWD; FY2024, 768.25 million TWD; FY2025, 501.49 million TWD.

Has Diamond Biotechnology made a profit in recent years?

Net income by fiscal year: FY2021, 41.92 million TWD; FY2022, 33.39 million TWD; FY2023, 46.74 million TWD; FY2024, 73.20 million TWD; FY2025, a loss of 70.31 million TWD. It reported a net loss in 1 of these 5 years.

Company Information

SectorHealthcare
IndustryTargeted Healthcare Equipment
HeadquartersTaipei, Taiwan
ExchangeTaipei Exchange
TimezoneAsia/Taipei (CST)

Contact & Links

Address
No. 95, Section 1, Taipei, 221
Phone
886 2 2755 3320
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Diamond Biotechnology Co., Ltd (6815.TWO)”, data as of Jun 30, 2026, https://dataporium.tech/stocks/6815.TWO

LinkedInLinkedInXXYouTubeYouTube